US 10772956
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 10772956 (Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Sep 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/397